Table 2.
Demographic features, treatment approaches, and clinical outcomes of patients with COVID-19 (N = 60)
| Variables | Number (n) | Percentage (%) |
|---|---|---|
| Age (in years) | ||
| ≤40 | 40 | 66.66 |
| 41–60 | 10 | 16.67 |
| >60 | 10 | 16.67 |
| Sex | ||
| Male | 41 | 68.33 |
| Female | 19 | 31.67 |
| Comorbidities and preexisting pathologies (multiresponses) | ||
| Hypertension | 37 | 61.67 |
| Diabetes mellitus | 32 | 53.35 |
| Cardiac (heart failure, coronary artery disease, cardiomyopathies) | 32 | 53.33 |
| Asthma | 29 | 48.33 |
| Heart conditions (such as heart failure, coronary artery disease, or cardiomyopathies) | 26 | 43.33 |
| Chronic lung disease (COPD, interstitial lung disease, pulmonary hypertension, bronchopulmonary dysplasia, bronchiectasis, cystic fibrosis) | 25 | 41.67 |
| Tuberculosis | 12 | 20 |
| Chronic liver disease (cirrhosis, nonalcoholic fatty liver disease, alcoholic liver disease, autoimmune hepatitis) | 10 | 16.67 |
| Mental health disorders (mood disorders including depression and schizophrenia spectrum disorders) | 10 | 16.67 |
| Chronic kidney disease | 8 | 13.33 |
| Use of corticosteroids or other immunosuppressive medications | 6 | 10 |
| Cancer | 5 | 8.33 |
| Cerebrovascular diseases | 4 | 6.67 |
Data are shown as numerical values as well as percentage of total patients. COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease in 2019